The Novel Technology:
This technology describes synthesis of two dendrimers - a) second generation methoxy PEG dendrimer [mPEG(G2)(Cl)4] with four active chloride groups on the periphery and methoxy PEG as the core and b) second generation acetal PEG dendrimer [acetal[PEG(G2)(Cl)8] with eight active chloride groups on the periphery and 3,3-diethoxy-1,2-propanediol as the core. Further, in the intermediate generations, hydroxyl groups are present on the periphery that could be used for conjugation of the bioactive molecules. These hydroxyl groups can also be modified to other functional groups according to the need.
Applications:
- To use for effective cancer therapy through efficient active molecule delivery
- To have potential use in Drug delivery through conjugation of active bio molecules
Advantages:
- Conjugating dendrimers and bioactive molecules to increase therapeutic efficacy and delivery of bioactive molecules
- Less cytotoxicity towards healthy cells
Business Model:
This invention is in early stage of development. Experiments using other bioactive molecules are to be conducted. Looking for potential licensee(s) interested in taking the technology to next step of development.
Principal Investigator(s): Prof. M. A. Vijiyalakhsmi, CBST
Invention ID: CMP-025
IP status: Patent Pending
Jurisdictions: India (IN), United States (US)
For more details, please write to: